Literature DB >> 6038301

Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.

V Caggiano, J Cuttner, A Solomon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6038301

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Management of multiple myeloma.

Authors:  J S Malpas
Journal:  Br Med J       Date:  1969-04-19

2.  [Electrophoretical, class and group distribution of "paraproteins" and normal immunoglobulins].

Authors:  A Fateh-Moghadam; R Lamerz; M Knedel; B Tsirimbas
Journal:  Klin Wochenschr       Date:  1971-04-15

3.  T-cell imbalances in patients with multiple myeloma: an analysis by monoclonal antibodies.

Authors:  C D Platsoucas; H J Hansen; J R Redman; S Berenson; B J Lee; B D Clarkson
Journal:  J Clin Immunol       Date:  1983-07       Impact factor: 8.317

4.  Polyclonal immunoglobulin deficiency in myelomatosis and macroglobulinaemia.

Authors:  M T Cwynarski; S Cohen
Journal:  Clin Exp Immunol       Date:  1971-02       Impact factor: 4.330

5.  PWM-induced generation of immunoglobulin-secreting cells in patients with multiple myeloma.

Authors:  G Sieber; B Enders; H Rühl
Journal:  Klin Wochenschr       Date:  1981-10-01

6.  Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.

Authors:  A Solomon; C L McLaughlin; J D Capra
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

7.  Anomalous urinary proteins in patients with serum M-components.

Authors:  W Pruzanski; M A Ogryzlo
Journal:  Can Med Assoc J       Date:  1971-04-03       Impact factor: 8.262

8.  Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.

Authors:  A Solomon
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.